Endocrine therapy by continuous androgen suppression has been used for the treatment of advanced prostate cancer. Intermittent androgen suppression is a novel approach to endocrine therapy. Although the potential bene®t of intermittent androgen suppression includes prolongation of the androgen-dependent state, there may be a risk of promoting tumour growth by androgen replacement. In patients treated with intermittent androgen suppression, initiation and discontinuation of androgen suppression are usually determined by the level of total prostate-speci®c antigen (PSA). However, optimal timing of androgen suppression is unknown. It was reported recently that the free-to-total PSA increased with the response of androgen suppression therapy. The present study was undertaken to examine the change in free-to-total PSA during androgen-independent progression and to estimate the critical level of free-to-total PSA required to avoid progression in the course of intermittent androgen suppression therapy.
Method
Twenty-two patients who had been treated with continuous androgen suppression and showed sequential increases in total PSA were recruited into the study. Age ranged from 47 to 84 y, with a mean AE s.d. of 70.4 AE 8.5 y. Clinical stages at diagnosis were stage C (two patients), stage D1 (one patient) and stage D2 (19 patients). Histological examination before treatment showed one case of well-differentiated adenocarcinoma, 12 cases of moderately differentiated adenocarcinomas and eight cases of poorly differentiated adenocarcinomas. Initial endocrine therapy was performed by medical or surgical castration plus anti-androgen in 15 cases, castration plus oestrogen in ®ve cases, and castration alone in two. The mean time interval from the start of therapy to the measurement of free-to-total PSA on progression was 35.5 AE 40.7 months (range: 1±146 months). Using 181 frozen sera (4±13 samples from each patient), free and total PSA levels were measured by the DPC and Tandem-R kits, respectively.
Results
Free-to-total PSA levels varied among the patients. Of the six patients who developed clinical systemic progression, free-to-total PSA showed a decreasing tendency in four cases, a¯uctuation in one case and an increase in one case. Two patients with local progression revealed ā uctuation of free-to-total PSA. Of the 12 patients with PSA failure alone, free-to-total PSA showed a decrease in two cases, a¯uctuation in nine and an increase in one. There was no obvious trend of change in free-to-total PSA by three patients who revealed 50% or more decline in total PSA by withdrawal of anti-androgen (anti-androgen withdrawal syndrome).
Conclusion
The ®ndings suggest that free-to-total PSA decreases on clinical progression in prostate cancer patients treated with androgen suppression. Patients treated with intermittent androgen suppression therapy and currently in the off-treatment period should therefore resume androgen suppression when free-to-total PSA returns to near the pretreatment level.
